Lifesci Capital Forecasts Opus Genetics FY2025 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Analysts at Lifesci Capital issued their FY2025 EPS estimates for Opus Genetics in a note issued to investors on Thursday, February 12th. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($0.65) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Lifesci Capital also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.48) EPS.

Several other research firms have also commented on IRD. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Wedbush initiated coverage on Opus Genetics in a research note on Wednesday, October 29th. They set an “outperform” rating and a $8.00 target price for the company. Brookline Capital Acquisition upgraded Opus Genetics to a “strong-buy” rating in a research report on Monday, December 1st. Piper Sandler initiated coverage on Opus Genetics in a report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price target for the company. Finally, B. Riley Financial began coverage on Opus Genetics in a research report on Wednesday, December 10th. They set a “buy” rating and a $9.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $7.75.

Opus Genetics Stock Performance

NASDAQ:IRD opened at $3.64 on Monday. The company’s 50-day moving average is $2.36 and its two-hundred day moving average is $1.91. Opus Genetics has a 1-year low of $0.65 and a 1-year high of $3.70. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a market capitalization of $251.01 million, a price-to-earnings ratio of -1.94 and a beta of 0.58.

Insiders Place Their Bets

In related news, Director Fighting Blindness Foundation sold 4,000,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $2.15, for a total value of $8,600,000.00. Following the sale, the director owned 5,492,171 shares in the company, valued at approximately $11,808,167.65. The trade was a 42.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cam Gallagher bought 83,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the purchase, the director owned 83,000 shares in the company, valued at $163,510. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 6.60% of the stock is owned by corporate insiders.

Institutional Trading of Opus Genetics

A number of large investors have recently modified their holdings of IRD. Johnson Investment Counsel Inc. purchased a new position in Opus Genetics in the fourth quarter valued at $40,000. Raymond James Financial Inc. increased its holdings in Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after purchasing an additional 11,000 shares during the period. Comerica Bank acquired a new stake in Opus Genetics in the 1st quarter valued at about $29,000. Regency Capital Management Inc. DE acquired a new stake in Opus Genetics in the 4th quarter valued at about $92,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Opus Genetics in the 4th quarter valued at about $157,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.